Lowest Price Guaranteed
Pages
250
Last Updated
June 2026
View Count
34001
The peptide therapeutics market, valued at USD 90.2 billion in 2025, is projected to reach USD 108.2 billion in 2026 and USD 233.6 billion by 2035, representing a CAGR of 8.9% during the forecast period 2026 to 2035.
To learn more about this report, request a free sample copy
Peptide therapeutics represent a rapidly growing class of biologic drugs composed of amino acid chains. These therapies offer high target specificity, favorable safety profiles, and strong therapeutic efficacy. These therapies mimic naturally occurring biological processes and have gained widespread adoption across metabolic disorders, cancer, hormonal deficiencies, and autoimmune diseases. In recent years, the commercial success of peptide-based drugs, particularly GLP-1 receptor agonists for obesity and type 2 diabetes, has further strengthened the role of peptides in modern drug development. Importantly, peptides accounted for approximately 10% of all new FDA drug approvals between 2020 and 2024, reflecting their growing importance within the pharmaceutical industry.
As a result, pharmaceutical companies continue to invest in peptide engineering, drug delivery technologies, and manufacturing infrastructure. These investments are intended to improve therapeutic performance and meet growing market demand. For instance, in December 2025, Eli Lilly announced multibillion-dollar investments in new manufacturing facilities to expand peptide production capacity and strengthen supply chain resilience. Further, advancements in peptide design and delivery technologies are expanding the therapeutic potential of peptide therapeutics, creating new opportunities for clinical and commercial adoption.
However, the industry still faces challenges related to manufacturing complexity, formulation constraints, and scalability of commercial production while maintaining stringent quality standards. Despite these limitations, the rising prevalence of chronic diseases such as obesity, diabetes, and cancer, coupled with a growing pipeline of peptide therapeutics, continues to create significant opportunities for stakeholders engaged in peptide drug development and manufacturing.
The growing adoption of peptide-based therapies for metabolic disorders continues to reshape the pharmaceutical industry. Highlighting this trend, Sebastian Arana (Head of Process Solutions, MilliporeSigma), in a roundtable discussion, stated, “GLP-1 therapies have rapidly evolved from diabetes to obesity and beyond, becoming one of the most transformative drug classes in recent history.”
Commenting on the future outlook of the industry, he further highlighted that, “The next wave of innovation will focus on oral peptides, multi-modal peptides, and small molecule GLP-1 receptor agonists that improve access and manufacturability. It’s a dynamic landscape and companies are racing to capture the opportunity, including both the well-known originators of today, and biotech, contract manufacturers, and generic developers.”
Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes detailed transcripts of the following third-party discussions:
Based on size of peptides, the global market is segmented into small peptides, medium peptides, and large peptides.
According to our market analysis, medium peptides capture close to 65% of the peptide therapeutics market share. This dominance reflects the industry's growing preference for therapeutic modalities that balance biological efficacy with commercial feasibility. While small peptides often face challenges related to rapid degradation and short circulation times, larger peptide and protein-based therapeutics frequently introduce manufacturing complexity and higher development costs. Medium-sized peptides effectively bridge this gap by offering strong target specificity, favorable pharmacokinetic properties, and relatively streamlined production processes. Additionally, advances in peptide engineering have enabled developers to enhance peptide stability and half-life without significantly increasing molecular complexity, further strengthening the commercial viability of this segment.
The market for small peptides is likely to grow at the highest CAGR during the forecast period. This is primarily because pharmaceutical companies are increasingly exploring small peptides as targeted therapeutic agents due to their ability to penetrate tissues more effectively, ease of manufacturing, and compatibility with several targeted drug delivery devices. As these companies continue to expand precision medicine initiatives, the investment activity within this segment is expected to accelerate significantly, thereby driving the peptide therapeutics market for small peptides.
Based on route of administration, the global market is segmented into intravenous, oral, subcutaneous, topical, and other routes.
Currently, the subcutaneous segment accounts for the largest share of the peptide therapeutics market. This dominance stems from its ability to deliver peptide drugs directly into systemic circulation while maintaining high bioavailability and therapeutic effectiveness. Since most peptides undergo enzymatic degradation in the gastrointestinal tract and exhibit limited intestinal absorption, pharmaceutical companies continue to rely on subcutaneous administration to ensure efficient systemic delivery. Moreover, subcutaneous injections enable self-administration, reduce dependence on healthcare facilities, and support long-term treatment regimens, making them particularly suitable for chronic conditions such as diabetes, obesity, and hormonal disorders. As a result, several commercially successful peptide therapeutics continue to utilize this route of administration.
In contrast, the topical segment is expected to witness the highest growth during the forecast period. Growing demand for non-invasive therapies, coupled with continuous advancements in permeation enhancement technologies, is encouraging developers to explore topical delivery approaches. As healthcare systems increasingly prioritize patient adherence and convenience, topical peptide therapeutics are emerging as an effective alternative for treatment applications.
On the basis of therapeutic area, the peptide therapeutics market is segmented into metabolic, oncological, endocrine, gastrointestinal disorders, and others.
Currently, metabolic disorders account for over 60% of the overall peptide therapeutics market share. This is primarily due to the substantial clinical and commercial success of peptide-based therapies such as GLP-1 receptor agonists for obesity and type 2 diabetes. Unlike many therapeutic areas where therapies focus on symptom management, peptide therapeutics for metabolic disorders have demonstrated the ability to regulate key metabolic pathways involved in appetite control, glucose homeostasis, and energy balance. This has driven strong adoption of peptide-based drugs within the metabolic disorders segment.
It is worth highlighting that the gastrointestinal disorders segment is likely to grow at a higher CAGR during the forecast period. This growth is driven by the increasing prevalence of gastrointestinal disorders and the growing need for targeted therapies capable of addressing complex disease mechanisms. Despite the availability of conventional treatment options, many gastrointestinal disorders continue to exhibit high relapse rates and limited long-term disease control, creating a significant unmet medical need. Consequently, peptide therapeutics are gaining traction for their ability to selectively modulate biological pathways and offer more targeted treatment approaches, thereby supporting the growth of this segment.
In terms of key geographical regions, the peptide therapeutics market is distributed across North America, Europe, Asia-Pacific, and Rest of the World.
According to our analysis, North America captures the largest share of the peptide therapeutics market, and this trend is expected to continue throughout the forecast period. The region benefits from a strong concentration of leading pharmaceutical companies, advanced drug development infrastructure, and significant investments in biologics research. Further, North America has emerged as a key commercialization hub for peptide therapeutics, supported by advanced drug development infrastructure, robust reimbursement systems, and early adoption of innovative peptide therapies. As a result, the region accounts for a major share of global peptide therapeutics development and commercialization activity.
The peptide therapeutics market in Asia-Pacific is expected to grow at the highest rate during the forecast period. This growth is primarily driven by increasing healthcare expenditure, improving access to advanced therapies, and the rapid growth of the pharmaceutical and biotechnology sectors across countries such as China, India, Japan, and South Korea. Further, governments and private investors across the region are actively supporting innovation and manufacturing expansion, creating a favorable environment for peptide therapeutics development.
For instance, in October 2025, PolyPeptide announced a major expansion of its peptide manufacturing facility in Ambernath, India, aimed at increasing production capacity by more than three times and strengthening its capabilities for complex peptide therapeutics. As regional companies continue to strengthen research and manufacturing capabilities, Asia-Pacific is expected to emerge as a key growth hub for the global peptide therapeutics market.
| Key Report Attributes | Details | |
| Historical Trend | Since 2021 | |
| Forecast Period | Till 2035 | |
| Market Size 2026 | USD 108.2 Billion | |
| Market Size 2035 | USD 233.6 Billion | |
| CAGR (Till 2035) | 8.9% | |
| Key Players Profiled |
|
|
| Segments Covered |
|
|
| Excel Data Packs (Complimentary) |
|
|
| PowerPoint Presentation (Complimentary) |
|
|
| Customization Scope |
|
|
Based on the research, we have segmented the Peptide Therapeutics Market into size of peptide, route of administration, key therapeutic area, and key geographical regions.
By Size of Peptide
By Route of Administration
By Key Therapeutic Area
By Key Geographical Regions